• Effective Small-scale Production of Antibodies.

Laboratory Products

Effective Small-scale Production of Antibodies.

Jan 23 2007

Using a CELLine 350 cell culture system, supplied by Integra Biosciences AG, the Institute for Molecular Medicine & Experimental Immunology (IMMEI) (Bonn, Germany) has transformed the effectiveness of its small-scale antibody production.

Designed for ease-of-use the CELLine 350 utilises proprietary membrane technology to separate off the cultivation chamber with an upper semi-permeable membrane through which nutrient can diffuse and a lower one that allows gases to diffuse. Separate ports allow selective access to the upper nutrient supply chamber and the central cultivation chamber. This novel compartmentalised arrangement means that medium can be exchanged without influencing the function or growth of the cells and gases. Consequently, traditional cell growth limitations brought about by a lack of nutrients or the accumulation of metabolic waste can be overcome just as easily as oxygen deficiency. Such optimised conditions promote significant cell growth and lead to drastically increased cell densities.

Cells growing under the optimal conditions created in CELLine reach densities of 107 to 108 cells per ml and the concentration of expressed protein is typically 50 to 100 times above what is found in standard cell culture disposables. By combining high product concentration with recurring product collection, large amounts of highly concentrated proteins are routinely obtained in CELLine. In the case of monoclonal antibodies (MAb), average concentrations range from 1 to 2 mg/ml of MAb (in both CELLine 350 and the larger CELLine 1000) and monthly yields typically range from 100 to 250 mg (using a CELLine 1000).

The CELLine has been designed to bring considerable cost savings to cell cultivation. The novel bioreactor drastically reduces the need for high capital investments in cell culture instrumentation or handling large amounts of cell culture disposables in order to be able to obtain milligram amounts of a designated protein. High production yields together with a 90% reduction in media supplement requirements enable further cost and time-savings in downstream processing steps.

Digital Edition

Lab Asia 29.6 Dec

November 2022

In This Edition Chromatography Optimising Viral Vector Purification Strategies with Multimodal Chromatography Key UHPLC Characteristics Required for High throughput LC-MS New Low Volum...

View all digital editions


CPhI & P-MEC China 2022 - NEW DATES

Dec 20 2022 Shanghai, China & Online 21 November 2022 to 13 January 2023

Smart Factory Expo 2023

Jan 25 2023 Tokyo, Japan

Arab Health

Jan 30 2023 Dubai, UAE

Nano Tech 2023

Feb 01 2023 Tokyo, Japan

Medlab Middle East

Feb 06 2023 Dubai, UAE

View all events